TECH
Status-Quo-PlayerBio-Techne
$57.53
+3.54%
as of 13 Apr
Power Core
The moat in one sentence: Bio-Techne's power derives from being the cited standard in biological reagents, where switching suppliers introduces scientific risk that researchers, journals, and regulators are structurally unwilling to accept.
Direction of Movement
Steady Core Recovery, Growth Segments Await Critical Mass
ROC 200
+2.9%
TECH
Bio-Techne
$57.53
+3.54%
as of 13 Apr
DCF Fair Value: $21.77
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Bio-Techne Corporation is a global developer, manufacturer and supplier of high-quality reagents, analytical instruments, and precision diagnostics serving the research, diagnostic, and bioprocessing markets worldwide. The company operates through two primary segments: protein sciences, which develops biological reagents including cytokines, growth factors, antibodies, and cell selection technologies; and diagnostics and spatial biology, which provides diagnostic reagents, molecular diagnostics, and spatial biology products. Bio-Techne maintains an extensive catalog of over 500,000 products, with approximately 95% manufactured in-house. Its portfolio includes flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Asuragen, and Tocris Bioscience, serving academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic laboratories, and government agencies. Headquartered in Minneapolis, Minnesota, the company operates manufacturing facilities, research centers, and customer support offices across North America, Europe, and Asia-Pacific, generating significant revenue from the United States while maintaining a strong international presence. Bio-Techne's reputation for high-quality proteomic reagents and instruments enables it to maintain strong margins and cash flow while supporting scientific discovery and clinical breakthroughs.